Eur Respir J 2010; 36: 417–427
DOI: 10.1183/09031936.00095609

Platelet-activating factor reduces endothelial nitric oxide production: role of acid sphingomyelinase

Y. Yang*,ƒ, J. Yin#,ƒ, W. Baumgartner¶, R. Samapati#, E.A. Solymosi#,+, E. Reppien§, W.M. Kuebler#,+, and S. Uhlig*,****

ABSTRACT: Platelet-activating factor (PAF) is a mediator of pulmonary oedema in acute lung injury that increases vascular permeability within minutes, partly through activation of acid sphingomyelinase (ASM). Since caveolae are rich in sphingomyelin and caveolin-1, which block endothelial nitric oxide (NO) synthase (eNOS) by direct binding, we examined the relationship between ASM, caveolin-1 and eNOS activity in the regulation of vascular permeability by PAF.

In caveolar fractions from pulmonary vascular endothelial cells (isolated from perfused rat lungs) the abundance of caveolin-1 and eNOS increased rapidly after PAF perfusion. PAF treatment decreased endothelial NO (eNO) formation as assessed by *in situ* fluorescence microscopy. Restoration of eNO levels with PAPA-NONOate ((Z)-1-[N-(3-ammoniopropyl)-N-(n-propyl)amino]diazen-1-ium-1,2-diolate) mitigated the PAF-induced oedema.

PAF treatment increased the ASM activity in caveolar fractions and perfusion with ASM decreased eNO production. Pharmacological inhibition of the ASM pathway with imipramine, D609 or dexamethasone blocked the PAF-induced increase of caveolin-1 and eNOS in caveolae, and the decrease in eNO production and oedema formation.

We conclude that PAF causes ASM-dependent enrichment of caveolin-1 in caveolae of endothelial cells, leading to decreased eNO production which contributes to pulmonary oedema formation. These findings suggest rapid reduction in eNO production as a novel mechanism in the regulation of vascular permeability.

KEYWORDS: Caveolin, endothelial nitric oxide synthase, nitric oxide, pulmonary oedema, steroids, vascular permeability

Platelet-activating factor (PAF) is an important regulator of vascular functions in the lungs [1]. The actions of PAF are mediated by lipid modifying enzymes: 1) cyclooxygenase and lipoxygenase, which produce thromboxane and leukotrienes that mediate vasoconstriction and bronchoconstriction [2]; and 2) cyclooxygenase and acid sphingomyelinase (ASM), which form prostaglandin (PG)E_2 and ceramide that increase vascular permeability [3, 4]. The molecular consequences of the PAF-induced activation of ASM in the pulmonary endothelium remain to be identified. ASM is a critical enzyme in sphingolipid biochemistry that, under conditions of inflammation or stress, can rapidly be activated to convert sphingomyelin to ceramide [5]. A well described consequence of ASM activation is formation of ceramide-rich membrane microdomains which are involved in several cell functions, such as stress signalling, apoptosis after death cell receptor stimulation and infection with various pathogens [5, 6]. Caveolae, which are abundant in endothelial cells, represent a specialised form of microdomains that contain high levels of sphingomyelin, as well as ASM activity [7].

Endothelial nitric oxide (NO) synthase (eNOS) is located inside caveolae and remains in its inactive state by binding to caveolin-1 [8]. Both caveolin- and eNOS-deficient mice show increased vascular permeability at inter-endothelial junctions, suggesting that these molecules are critical for vascular barrier functions in the lungs [9–11]. The localisation of eNOS at cellular membranes and its interaction with sphingolipids is considered a key aspect of eNOS signalling and function [12]. Taken

AFFILIATIONS
*Institute of Pharmacology and Toxicology, Medical Faculty, RWTH Aachen University,
¶Dept of Cellular Neurobionics, Institute of Biology 2, RWTH Aachen University, Aachen,
#Institute for Physiology, Charité Universitätsmedizin Berlin, Berlin, and
§Research Center Borstel, Division of Pulmonary Pharmacology, Borstel, Germany.
+The Keenan Research Centre, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, ON, Canada.
ƒThese authors contributed equally to this study.
**These authors are joint senior authors.

CORRESPONDENCE
S. Uhlig
Institute of Pharmacology and Toxicology, Medical Faculty
RWTH Aachen University
52074 Aachen
Wendlingweg 2
Germany
E-mail: suhlig@ukaachen.de

Received:
June 17 2009
Accepted after revision:
Oct 26 2009
First published online:
Nov 19 2009

European Respiratory Journal
Print ISSN 0903-1936
Online ISSN 1399-3003

This article has supplementary material accessible from www.erj.ersjournals.com

together, these findings suggest that an agent, such as PAF, which causes vascular permeability through activation of ASM, may do so by regulating the balance between caveolin-1 and eNOS in pulmonary endothelial cells.

In the lungs, exogenous NO has reduced vascular leak formation in animal models of acute lung injury [13, 14] and even in patients [15], although under certain conditions a blockade of NO production may be beneficial as well [16]. These, and other seemingly contradictory, findings have not yet been completely reconciled [17], although it seems likely that vascular permeability is increased by both too little and too much NO. In response to PAF, at least in the mesenteric artery, the effect of NO on vascular permeability appears to be biphasic: exogenous NO inhibits the rapid (0–10 min) as well as the secondary (>15 min) neutrophil-dependent effect [18]. While the latter effect is explained by the direct effects of NO on neutrophils [19], the mechanism of the first phase has not yet been elucidated. This rapid protective effect of exogenous NO would be explained if inflammatory mediators such as PAF caused a rapid drop in endothelial NO production. Herein, we tested this hypothesis. Our findings show that PAF rapidly decreases endothelial NO production by sphingomyelinase-dependent mechanisms inside caveolae.

MATERIALS AND METHODS

A detailed material and method section is provided in the supplementary data (supplement 1).

Animals

Male Sprague-Dawley rats (350–450 g for *in situ* fluorescence imaging) and female Wistar rats (weight 220–250 g for all other experiments) were maintained on a standard laboratory chow (V1534-000 sniff R/M; Ssniff Spezialdäten GmbH, Soest, Germany) and water *ad libitum*.

Preparation of isolated, ventilated and perfused rat lungs

Rat lungs were prepared, perfused and ventilated as described previously [20]. Briefly, lungs were perfused through the pulmonary artery at a constant hydrostatic pressure (12 cm H_2O) with Krebs-Henseleit-buffer. Perfusate buffer contained 2% albumin, 0.1% glucose and 0.3% HEPES. Oedema formation was assessed by continuously measuring the weight gain of the lung. Imipramine (final concentration 10 μM), D609 (300 μM), L-NAME (L-nitro-arginine-methyl-ester) (100 μM), dexamethasone (10 μM) and PAPA-NONOate ((Z)-1-[N-(3-ammoniopropyl)-N-(n-propyl)amino]diazen-1-ium-1,2-diolate) (100 μM) were added to the buffer reservoir 10 min prior to PAF administration. ASM (1 $U \cdot mL^{-1}$ in perfusate buffer) was continuously infused for 30 min into venular capillaries of isolated lungs *via* a venous micro-catheter. The lung filtration coefficient (K_f) was measured by suddenly raising or lowering the perfusion pressure by 5 cm H_2O and analysing the resulting weight transients by bi-exponential regression as described previously [21]. Fluid fluxes into and out of the alveolar space were quantified by a double-indicator dilution technique as previously described [22].

Preparation of endothelial membrane fractions

In order to demonstrate that PAF increases the amount of Cav1 and eNOS inside caveolae from pulmonary endothelial cells *in situ*, we used perfusion with silica beads to tag the endothelial cells and separate their plasma membrane fractions in a sucrose gradient [23]. We have modified the published procedure and used a slightly different gradient (fig. 1) in order to expand the range where caveolae are found. Usually, when working with sucrose gradients caveolae are found in the fractions containing 10–20% sucrose [23]. After flow rate was reduced to 3 $mL \cdot min^{-1}$, perfusion with 1% cationic colloidal silica beads was started. The lungs were homogenised, mixed with an equal volume of 1.02 $g \cdot mL^{-1}$ Nycodenz® (Axis-Shield PoC, Oslo, Norway) and layered over 0.5–0.7 $g \cdot mL^{-1}$ Nycodenz containing 60 mM sucrose. After centrifugation at 72,128 $\times g$ (30 min, 4°C) the pellet containing the silica-coated endothelial membranes fragments was resuspended with 1 mL MBS (20mM MES, 150 mM NaCl pH 6.0) and 10% Triton-X-100 (final concentration of 1%) was added to the membranes for 60 min at 4°C. Subsequently, the suspension was homogenised and mixed with 80% sucrose to achieve a 40% membrane-sucrose-solution. A 30% to 5% sucrose gradient was layered on top. Samples were centrifuged at 4°C and at 109,368 $\times g$ for 16–18 h. Volumes of 3×150 μL were sampled from the top to the bottom and collected as five membrane fractions. The pellet was solubilised in 150 μL MBS (pellet fraction).

Gel electrophoresis and immunoblotting

Equal amounts of protein (5 μg) were separated by SDS polyacrylamide gel electrophoresis (12% for Cav-1, 8% for eNOS) and transferred to nitrocellulose. After transfer, nitrocellulose sheets were blotted with respective antibodies. ASM activity was determined as described previously [4].

In situ *fluorescence microscopy*

In situ imaging of endothelial NO production was performed as previously described [24] using membrane-permanent DAF-FM (4-amino-5-methylamino-2′,7′-difluorofluorescein diacetate) diacetate (5 $\mu M \cdot L^{-1}$). NO-sensitive DAF-FM was infused for 20 min into pulmonary capillaries *via* a venous micro-catheter. Single venular capillaries were viewed at a focal plane corresponding to maximum diameter (17–28 μm). Fluorescence images obtained in 10-s intervals were background corrected and fluorescence intensity (F) was expressed relative to its individual baseline (F_0). Since the conversion of DAF-FM to the benzotriazole derivative is irreversible, NO production is reflected by changes of the ratio F/F_0 ($\Delta F/F_0$) over time and was determined in 5-min intervals.

Statistics

In case of heteroscedasticity, data were transformed by the Box-Cox transformation prior to analysis. Data were analysed by an unpaired t-tests or by the Dunnett test (JMP® statistical software version 7; JMP Germany, Böblingen, Germany). Fluorescence data were analysed by the Kruskal–Wallis and Mann–Whitney U-test. If required, p-values were corrected for multiple comparisons according to the false-discovery rate procedure using the ''R'' statistical package (R Foundation for Statistical Computing, Vienna, Austria).



FIGURE 1. Caveolin (Cav)1 content of pulmonary endothelial cell plasma membrane fractions. a) Immunoblots showing the cav1 distribution in pulmonary endothelial cell plasma membrane fractions from untreated (control) and platelet-activating factor (PAF)-treated (10 min after bolus injection of 5 nmol PAF) isolated perfused rat lungs. b) Immunoblots showing angiotensin converting enzyme distribution in the same samples. c) Pooled immunoblots showing Cav1 distributions from untreated (n=4) and PAF-treated (n=4) isolated perfused rat lungs from fraction A–E. d) Immunoblots showing Cav1 in fractions from whole endothelial cells (n=3), from the pooled fractions B and C (n=3) and from the remainder of the endothelial cells without the fractions B and C (n=3). The latter two fractions (B/C and the remainder) were obtained from the same preparation. □: control; ■: PAF. Data are presented as mean±SD. *: $p<0.05$ *versus* control.

RESULTS

PAF increases Cav-1 in membrane fractions

Lungs were perfused for 50 min before perfusion with the colloidal silica beads was started in order to prepare endothelial cell membrane fractions. Immunoblotting of the resulting fractions showed a typical distribution for flotillin (data not shown) and Cav-1 (fig. 1a); two bands are typical for rat Cav-1 representing cav1α and cav1β [25]. Angiotensin converting enzyme (ACE) (fig. 1b) and the transferrin receptor (data not shown), markers of non-raft membrane fractions, were only present in the fractions with the highest density, confirming that the membrane fractions prepared by silica coating procedure were not contaminated by proteins from extra-caveolar/extra-raft membranes. To increase the amount of material available for subsequent analyses, we pooled the 17 fractions into five fractions labelled A–E. In line with previous work [23], the sucrose concentrations, the presence of Cav-1 and the absent or weak signals for ACE, we consider fractions B and C to represent caveolae, while fraction D may represent a mixture of caveolar and non-caveolar structures. In most cases, the fractions from the different experiments were analysed on separate gels; however, similar results were obtained when fractions were analysed on the same gel (see supplement 2 in the supplementary data).

Compared to untreated lungs, PAF caused an increase in the amount of Cav1, but not ACE, in several fractions from pulmonary endothelial cells (fig 1). In addition, the effect of PAF was clearly noticeable in the pooled fractions; the strongest increase in Cav1 was noted in the fractions B, C and D (fig. 1c). To demonstrate that Cav1 was recruited to the caveolae, we measured the abundance of Cav1 in whole cell lysates, in the pooled fractions B/C representing the caveolae and in the remainder of the cells (fractions A, D, E and pellet) representing the non-caveolar fractions (fig. 1d). Our findings show that the total amount of Cav1 was unchanged in the total endothelial cell lysate but that it was increased in the caveolar fractions and decreased in the remaining fractions.

Number and size of caveolae

Because Cav1 is the signature molecule of caveolae we examined whether PAF-treatment increased the number of caveolae by analysing electron microscopic images of microvascular endothelial cells from isolated perfused lungs (fig. 2a and b). PAF did not increase the number of apical, cellular or basal caveolae (fig. 2c), nor did it increase the size of caveolae: the maximal diameter at the centre of caveolae was 152±26 nm (n=103, from one lung) in control and 148±26 nm (n=106, from one lung) in PAF-treated lungs. These results are consistent with those of animals over-expressing endothelial Cav1 that also did not show altered numbers of caveolae [26]. Furthermore, in PAF-treated lungs, we repeatedly observed loosening of the endothelial adherence junctions between cells in the capillaries (fig. 2b).

Effect of PAF on caveolar eNOS and NO production

As Cav1 binds and thereby blocks eNOS activitaction [8], we investigated the effect of PAF on the abundance of eNOS inside caveolae and on endothelial NO formation.

PAF increased the amount of eNOS inside the caveolar fractions B and C (fig. 3a). Imaging of DAF-FM loaded lung capillary endothelial cells *in situ* revealed stable and continuous NO production in control lungs (fig. 3b; representative images discussed later) that was completely blocked after addition of the NO synthase inhibitor L-NAME (fig. 3b). Addition of the NO donor *S*-nitroso-*N*-acetylpenicillamine elicited a consistent rapid and marked increase of fluorescence at the end of all experiments (data not shown). These findings indicate adequate fluorophore labelling and confirm that the fluorescence yield was not affected by the pharmacological interventions *per se*. PAF treatment markedly reduced basal endothelial NO production for >30 min (fig. 3b).

To test the effect of NO on PAF-induced oedema formation, NO levels were increased (PAPA-NONOate) or decreased (L-NAME) by pharmacological means. Given alone, both agents did not alter lung weight (fig. 3c). Exogenous application of NO by perfusing lungs with PAPA-NONOate attenuated PAF-induced oedema formation, while inhibition of NO synthase activity by L-NAME had no effect (fig. 3c).



FIGURE 2. Number and size of caveolae. Electron microscopic images of endothelial cells showing junctions and caveolae in a) control and b) platelet-activating factor (PAF)-treated lungs. Scale bars=1 μm. c) Number of apical (□), basal (■) and intracellular (■) caveolae in endothelial cells from control and PAF treated lungs. 95–106 apical, basal and midcellular caveolae were counted from one control and one PAF-treated lung.

As NO has been involved in the regulation of the epithelial barrier [22], it was important to examine whether the intravascular application of PAF would alter alveolar fluid influx or absorption. Using a double-indicator technique and assuming a two-compartmental distribution model [22], we found that PAF did not alter the alveolar barrier properties (fig. 4a and b).

A tight alveolar barrier is also important for the gravimetric measurement of K_f. K_f represents the hydraulic conductance of the pulmonary endothelium and can only be determined if the alveolar hydraulic conductance remains stable, as otherwise the measured value represents the sum of both conductances [21]. In addition, an isogravimetric state, a prerequisite for the measurement, is difficult to achieve in case of alveolar oedema. Because PAF did not increase alveolar permeability or fluid absorption we went on to measure the K_f. Figure 4c illustrates a typical K_f measurement manoeuvre demonstrating that the weight transient induced by the pressure jump was reversible even after PAF, *i.e.* that another critical requisite for the K_f measurement was valid.

Given alone, the NO donor PAPA-NONOate did not increase the K_f, whereas L-NAME increased the K_f to approximately half the value of PAF (fig. 4d). Given 10 min before PAF, PAPA-NONOate attenuated the PAF-induced K_f increase, while L-NAME had no effect (fig. 4d).

Role of ASM

10 min after the addition of PAF, ASM activity was increased in the fractions A–C (fig. 5a). Imipramine and the steroid dexamethasone, which both prevent the PAF-induced activation of ASM and oedema formation [4], abolished the PAF-induced increase in ASM activity in the membrane fractions (fig. 5a). Perfusion with ASM markedly decreased endothelial NO production (fig. 5b).

Imipramine and D609, two structurally different inhibitors of the ASM pathway [5], prevented the PAF-induced recruitment of Cav1 to caveolar membrane fractions (fig. 6a and b). Furthermore, imipramine blocked the PAF-induced recruitment of eNOS (fig. 6c). In line with previous findings [4], imipramine and D609 reduced the PAF-induced oedema formation in these experiments (fig. 6d). Finally, imipramine attenuated the PAF-induced decrease in endothelial NO production (fig. 7a and b). Imipramine alone (given 10 min before PAF; t= -10 min) had no effect on basal NO production, as demonstrated by similar NO production rates at baseline (t=0 min).

Effects of dexamethasone

Because steroids provide an independent pharmacological approach to block ASM activity in this model (fig. 5 [4]) and because the short-term anti-inflammatory mechanisms of steroids are still poorly understood, we studied the effects of dexamethasone on Cav1 and eNOS recruitment, NO



FIGURE 3. Effect of platelet-activating factor (PAF) on caveolar endothelial nitric oxide synthase (eNOS) and nitric oxide (NO) production. a) Immunoblots showing eNOS distribution in pooled pulmonary endothelial cell plasma membrane fractions from untreated (control) and PAF-treated (10 min after bolus injection of 5 nmol PAF) isolated perfused rat lungs. □: control; ■: PAF. *: $p<0.05$ *versus* control. Data are presented as mean±SD (n=4). b) Endothelial NO production as determined by *in situ* real-time fluorescence microscopy shown as 5-min averages in control (□), PAF (●) (bolus injection of 5 nmol PAF after baseline recording) and L-NAME (L-nitro-arginine-methyl-ester) (◇) (250 μM) treated lungs. NO production was quantified as an increase in fluorescence of DAF-FM (4-amino-5-methylamino-2',7'-difluorofluorescein diacetate) loaded endothelial cells over 5-min intervals relative to baseline $\Delta F/F_0$. The arrow indicates where PAF and L-NAME were added. *: $p<0.05$ *versus* control. Data are presented as mean±SEM (n=5). c) Weight gain in lungs perfused under control conditions (n=11) or with PAF (5 nmol; n=12), NONOate/PAF (100 μM NONOate; n=7), L-NAME/PAF (250 μM L-NAME; n=8), NONOate (n=3) or L-NAME (n=3). The pharmacological agents were added after 30 min of perfusion and PAF after 40 min of perfusion. Data are presented as mean±SD. *: $p<0.05$ *versus* control; #: $p<0.05$ *versus* PAF.

production and oedema formation. Treatment of perfused rat lungs with dexamethasone reduced the abundance of Cav1 in caveolar fractions in PAF-treated lungs (fig. 8a). Moreover, dexamethasone attenuated the PAF-induced increase in caveolar eNOS expression (fig. 8b), and the decrease in endothelial NO production (fig. 7b) and lung oedema formation (fig. 8c).

It has previously been shown that quinine attenuates the PAF-induced oedema formation [27] and that the effect of quinine is located somewhere along the ASM pathway has been speculated [1]. While quinine reduced the PAF-induced weight gain (fig. 8c), it had no effect on the enhanced expression of Cav1 in fractions B, C and D of PAF-stimulated lungs (fig. 8a).

DISCUSSION

Our study shows that a reduction in endothelial NO formation contributes to increased pulmonary vascular permeability under pathophysiological conditions mimicked by PAF. These findings are consistent with previous studies showing increased vascular permeability in eNOS-deficient mice [10, 11]. Our findings further indicate that PAF reduces endothelial NO levels by the ASM-dependent recruitment of Cav1 to caveolae with subsequent inhibition of eNOS, providing the first mechanistic explanation for the role of ASM in the development of pulmonary oedema [4]. Our findings may also provide a rationale for the treatment of pulmonary oedema with exogenous NO or NO donors in order to restore normal endothelial NO levels. Interestingly, acute lung injury patients with higher urinary NO levels had reduced mortality and patients experienced more ventilator-free days and more organ failure-free days [28]. Finally, our observations raise the hypothesis that interference with ASM activity inside caveolae may explain some of the short-term effects of steroids.

Role of NO in PAF-induced oedema formation

The role of NO in the development of pulmonary oedema remains controversial [17]. Probable reasons to explain conflicting reports showing either attenuation [16] or aggravation [29, 30] of pulmonary oedema by NO synthase inhibitors are: 1) the different timing of the measurements; 2) the numerous and diverse effects of NO on leukocytes and endothelial cells; and 3) the notion that both too much and too little NO can increase vascular permeability [11]. The model of the isolated blood-free perfused rat lung allows circumvention of most of these confounders. 1) *In vivo*, the PAF-induced oedema formation appears to consist of two phases: an early phase (<10 min) caused by a direct effect on the vascular endothelium and a later phase (>20 min) mediated by PAF-activated leukocytes [31]. The focus on the



FIGURE 4. Alveolar fluid influx, alveolar fluid absorption and filtration coefficient. a) Alveolar fluid influx and b) alveolar fluid absorption in control lungs (□), platelet-activating factor (PAF)-treated lungs (■) and lungs exposed to 20 cm H_2O hydrostatic pressure for 60 min (■). c) Weight gain in a typical experiment with administration of PAF and determination of the filtration coefficient (K_f). For the K_f measurement, perfusion pressure was raised by 5 cm H_2O for 15 min and reduced back to baseline. Both weight transients (up and down) were used to calculate the K_f. - - - -: PAF: mean weight gain. d) K_f determined as the difference in K_f before and 10 min after injection of PAF. Lungs perfused under control conditions (n=3), with PAF (5 nmol; n=4), NONOate/PAF (100 μM NONOate; n=3), L-NAME (L-nitro-arginine-methyl-ester)/PAF (250 μM L-NAME; n=3), NONOate (n=3) or L-NAME (n=3). The pharmacological agents were added after 30 min of perfusion and PAF after 40 min of perfusion. Data are presented as mean±SD. *: $p<0.05$ *versus* control; #: $p<0.05$ *versus* PAF.

first 10 min and the absence of leukocytes in our model [32] allowed us to exclusively study the early effects of PAF on the pulmonary endothelium. 2) NO affects neutrophils in various ways [19], so that in intact animals the effect of NO inhibitors is difficult to interpret. Again, blood-free perfusion allows the exclusion of such complications. 3) It is well established that both too little or too much NO can aggravate pulmonary oedema [33], which has been explained in terms of the different amounts of NO being produced by eNOS (low NO levels) and inducible NOS (high NO levels) [34]. Given the short time span of our experiments, a role of inducible NOS in our model appears highly unlikely. Another potential concern



FIGURE 5. Role of acid sphingomyelinase (ASM). a) ASM activity in pooled pulmonary endothelial cell plasma membrane fractions from untreated (control) and platelet-activating factor (PAF)-treated isolated perfused rat lungs. Membrane fractions in lungs perfused for 50 min are shown under control conditions, with PAF (5 nmol) alone, with dexamethasone (10 μM) and PAF (Dex/PAF) or with imipramine (100 μM) and PAF. Pharmacological agents were added after 30 min of perfusion and PAF after 40 min. The perfusion was stopped after 50 min and endothelial cell membrane fractions were prepared and analysed for ASM enzymatic activity. Data are presented as mean±SD (n=4). *: $p<0.05$; **: $p<0.01$ *versus* PAF. b) Endothelial nitric oxide (NO) production as determined by *in situ* real-time fluorescence microscopy shown as 5-min averages in control (○) and ASM (●) (1 U·mL^{-1}) treated lungs. NO production was quantified as an increase in fluorescence of DAF-FM loaded endothelial cells over 5-min intervals relative to baseline $\Delta F/F_0$. The arrow indicates the addition of ASM. Data are presented as mean±SEM (n=5). *: $p<0.05$ *versus* control.



FIGURE 6. Effects of acid sphingomyelinase (ASM) pathway inhibitors on caveolar a) caveolin (Cav)-1 and b) endothelial nitric oxide synthase (eNOS). Immunoblots showing the Cav1 distribution in pooled pulmonary endothelial cell plasma membrane fractions prepared from lungs perfused with PAF alone (□), with imipramine (100 μM) and PAF (■) or with D609 (300 μM) and PAF (■). a, b) The panels are from two independent experimental series. The pharmacological agents were added after 30 min of perfusion and PAF after 40 min. The perfusion was stopped after 50 min and endothelial cell membrane fractions were prepared and analysed by immunoblotting. c) The lung weight gain from the same experiments. □: controls. Data are shown as mean±SD (n=4). *: $p<0.05$ *versus* PAF.

arises from the observation that NO is involved in the regulation of alveolar epithelial barrier functions, and thus that the effect of PAPA-NONOate might be on the alveolar epithelium rather than on the endothelium. Therefore, it was important to show that PAF does not cause alveolar oedema or alter alveolar fluid absorption in our model (fig. 4). Our findings support the notion that the isolated perfused rat lung is a useful tool to study the effects of PAF on the pulmonary endothelium. We would also like to emphasise that PAF appears to increase vascular permeability by a very well regulated mechanism that leads to interstitial but not alveolar oedema (fig. 4).

Using this model we have shown, for the first time, that PAF rapidly attenuates endothelial NO production which in turn contributes to enhanced vascular permeability, as is illustrated by the effects of L-NAME and PAPA-NONOate on weight gain and K_f (figs 3c and 4d). This conclusion is concordant with altered endothelial junctional permeability in eNOS-deficient or L-NAME-treated mice [10, 11] and with the finding that endothelial NO synthesis reduces K_f in hydrostatic lung oedema [35]. The view that a drop in endothelial NO production promotes vascular permeability is further supported by the finding that oedema formation was attenuated if the PAF-induced decrease in endothelial NO levels was prevented by imipramine or dexamethasone. Other studies have reported that NO donors also reverse the PAF-induced protein clearance in the intestine [36].

However, it is important to note that L-NAME alone had no effect on lung weight, despite the fact that it increased the K_f. This is similar to the observation in eNOS-deficient mice that also showed increased vascular permeability but no lung oedema [11]. These findings suggest that the role of the PAF-induced cessation of NO production is to amplify the increase in vascular permeability which is caused by another mechanism. Hence, along the PAF-ASM-axis additional mechanisms are likely to come into play, such as PGE_2 [3] or calcium [1].

The present data help to explain many previous findings on the role of NO in the regulation of vascular permeability during PAF-mediated inflammation. However, they contradict other studies on PAF that show increased NO levels in bovine coronary venular endothelial cells [37] and rat blood-free perfused mesenteric venules [38], and protection against the increase in hydraulic conductivity by NO synthase inhibition or interference with the Cav1-eNOS interaction site [37, 39]. In contrast to our findings, it was observed that upon stimulation with PAF eNOS rapidly translocated to the cytosol [37] rather than accumulating in the membrane. Obviously, neither leukocytes, timing nor species differences are likely to explain all these discrepant findings. One possible explanation is that this differential regulation of NO represents another example of the frequently contrarian regulatory mechanisms of the systemic and the pulmonary circulation, for example high *versus* low arterial blood pressure or hypoxic dilatation *versus* hypoxic constriction. However, that would not explain why



FIGURE 7. Effects of inhibitors on platelet-activating factor (PAF)-mediated decrease in endothelial nitric oxide (NO). a) Representative fluorescence images of DAF-FM loaded lung venular capillaries in isolated perfused rat lungs. Images were obtained at a, c, e) baseline and b, d, f) 10 min after PAF (5 nmol) stimulation in control lungs (a, b) and in lungs perfused with either imipramine (100 μM) (c, d) or dexamethasone (10 μM) (e, f). The pharmacological agents were added 10 min prior to PAF infusion. Due to the irreversible conversion of the fluorescent dye, absence of fluorescence increase as seen in PAF treated controls indicates lack of NO synthesis. g) Endothelial NO production as determined by *in situ* real-time fluorescence microscopy shown as 5 min averages at baseline and after stimulation with PAF (△), imipramine/PAF (○) or dexamethasone/PAF (□) perfused lungs. NO production was quantified as increase in fluorescence of DAF-FM loaded endothelial cells over 5 min intervals relative to baseline $\Delta F/F_0$. The arrow indicates where PAF was added. Data are presented as mean±SEM (n=5). *: $p<0.05$ *versus* PAF.

NO donors are protective against PAF-induced oedema in both the lungs [16] and the intestine [36]. Alternatively, these differences might be explained in terms of the bell-shaped dose–response curve of NO where either too little or too much NO increases vascular permeability. Another important factor may be the basal NO tone, as endothelial NO production is highly dependent upon shear stress, thus studies in the absence of significant shear stress may be biased by low initial NO levels.

Regulation of Cav1 by PAF

Our study showed a rapid increase in the caveolar fractions of both Cav1 and eNOS after stimulation with PAF. Indirect evidence for the recruitment of Cav1 in response to PAF is provided by the fact that at the same time PAF decreased endothelial NO production. Most caveoli are expected in the 10–20% sucrose fraction [23] that roughly corresponds to our fractions B and C, which were largely devoid of ACE. While fraction A (8–10% sucrose) and fraction D (20–30%) may also contain some caveolae, our data do not exclude the possibility that Cav1 was recruited to membrane fractions distinct from caveolae.

Our findings provide some indications as to the source of the Cav1 that translocates to the caveolae in response to PAF. Figure 1d shows that the total amount of Cav1 remains unchanged and that the increase in the caveolae (fractions B/C) was matched by a decrease in the remainder of the cells. As this remainder consists of the entire cells except the caveolae, it is tempting to speculate that Cav1 was recruited from inside the cell. In fact, recruitment of Cav1 to the plasma membrane has previously been described for bovine aortic endothelial cells in response to prolonged laminar shear stress [40], and also in experimental models of coronary ischaemia reperfusion [41], portal hypertension [42] and liver cirrhosis [43]. In the latter studies, elevated Cav1 levels were associated with reduced NO synthesis. However, these studies have not identified the responsible mediators, examined NO levels in endothelial cells or identified a molecular mechanism to explain the recruitment of Cav1 to caveolae. Based on our findings it might be interesting to examine the role of sphingomyelinase in these and other clinically relevant situations [44, 45] that are characterised by reduced NO production.

Our conclusion that the PAF-induced redistribution of Cav1 is mediated by ASM is supported by several findings. 1) Using pharmacological tools (imipramine, D609 and steroids) and ASM-deficient mice it has previously been shown that the PAF-induced pulmonary oedema is mediated by ASM [4]. 2) While it has previously been shown that PAF increases circulating ASM levels, herein we demonstrate that PAF increases ASM activity inside endothelial caveolae. While the absolute increase in ASM activity may appear modest, the increase shown is enough to convert ~8% of the sphingomyelin in the plasma membrane to ceramide within the 10-min period that the PAF response lasts for (see supplement 3 in the supplementary data). In addition, it needs to be considered that some of the ASM is released into the buffer/serum so that the caveolar ASM activity will underestimate the extent of ASM activation/recruitment [4]. Since no reliable ASM antibodies are available we could not directly examine whether the increased activity is related to elevated amounts of enzyme. However, since recent studies have shown that receptor ligands can stimulate transfer of ASM from lysosomes to the



FIGURE 8. Effects of dexamethasone on a) caveolin (Cav)-1, b) endothelial nitric oxide synthase (eNOS) and c) weight gain. a) Immunoblots showing the Cav1 distribution in pooled pulmonary endothelial cell plasma membrane fractions prepared from lungs perfused under control conditions (□), with platelet-activating factor (PAF; 5 nmol) alone (■), with dexamethasone alone (100 μM) (▫), with dexamethasone and PAF (▪) or with quinine (100 μM) and PAF (■). The pharmacological agents were added after 30 min of perfusion and PAF after 40 min. The perfusion was stopped after 50 min and endothelial cell membrane fractions were prepared. b) The eNOS distribution in the same samples as shown in (a). c) Weight gain in the same experiments as shown in (a). Data are presented as mean±SD (n=4). *: $p<0.05$ *versus* PAF.

plasma membrane [46], such a transfer appears possible. Interestingly, activation of ASM by the fas ligand prevented (NO-dependent) bradykinin-induced vasodilation in coronary arteries [46], which is in line with the current findings. 3) By measuring the ASM activity inside caveolar fractions we demonstrated that imipramine, which is not an enyzme inhibitor but accelerates the proteolytic degradation of ASM [5], reduced the ASM activity below baseline levels. 4) Injection of ASM reduced endothelial NO production similar to PAF, providing direct evidence for the ability of ASM to affect eNOS. Unfortunately, the effect of ASM on Cav1 and oedema formation could not be examined because such measurements had to be performed in an isolated lung model with 100 mL of recirculating buffer, thus the required amounts of ASM were beyond feasibility. 5) The reduction of caveolar ASM activity by imipramine resulted in reduced caveolar levels of Cav1 and eNOS and finally in continued NO production despite the presence of PAF, and inhibition of oedema formation. This is in keeping with findings in a model of coronary ischaemia and reperfusion, where desipramine reduced the interaction between Cav1 and eNOS and improved cardiac functions [41]. The specificity of imipramine for ASM under these conditions is further supported by the finding that D609, an ASM-pathway inhibitor which is structurally completely unrelated to imipramine, also prevented the PAF-induced redistribution of Cav1 (fig. 6). 6) Finally, the same line of evidence as for imipramine could also be shown for dexamethasone. Dexamethasone was previously shown to prevent the PAF-induced increase in ceramide and oedema formation [4]. Herein we show that dexamathasone prevented the PAF-induced increase of ASM activity in endothelial caveolae and all its sequelae such as Cav1 and eNOS recruitment to the plasma membrane, the loss of endothelial NO production and subsequent formation of lung oedema. These findings concerning dexamethasone are not only of interest because they corroborate the conclusions of our study, but also because they suggest a novel hypothesis on how to explain the poorly understood short-term effects of steroids that have already been linked to caveolae [47]. It seems possible that steroids attenuate the formation of ceramide-rich microdomains, which are required for many signalling events [5], by interfering with the activation of ASM.

The present findings indicate that PAF increases vascular permeability by the ASM-dependent enrichment of Cav1 inside caveolae, which in turn inhibits eNOS and blocks NO synthesis. Several steps in this process require further definition. Recent studies indicate that sphingomyelinase produces ceramide to stabilise membrane microdomains [48], yet it remains to be shown how this favours the redistribution of Cav1 to caveolae. Furthermore, it needs to be examined whether PAF, similar to fas ligand [46], causes ASM recruitment from lysosomes to the plasma membrane.

Taken together our findings suggest that blockade of basal eNOS serves as a physiological mechanism to promote vascular permeability in the lungs. Activation of ASM and subsequent recruitment of Cav1 to the plasma membrane mediate this PAF-induced effect. These observations provide the first mechanistic clues about downstream targets of PAF-activated ASM metabolites and give a rationale for the

substitution of endogenous endothelial NO levels or activation of downstream signals as potential therapeutic targets in permeability-type lung oedema.

SUPPORT STATEMENT

This study was funded by the Deutsche Forschungsgemeinschaft (Bonn, Germany) within the SPP1267 (Sphingolipids and disease) and the Kaiserin-Friedrich Foundation (Berlin, Germany).

STATEMENT OF INTEREST

None declared.

ACKNOWLEDGEMENTS

We would like to thank B. Lindner (Research Centre Borstel, Borstel, Germany) for help with the analysis of the membrane fractions.

REFERENCES

1 Uhlig S, Göggel R, Engel S. Mechanisms of platelet-activating factor (PAF)-mediated responses in the lung. *Pharmacol Rep* 2005; 57: Suppl., 206–221.
2 Uhlig S, Wollin L, Wendel A. Contributions of thromboxane and leukotrienes to platelet-activating factor-induced impairment of lung function in the rat. *J Appl Physiol* 1994; 77: 262–269.
3 Göggel R, Hoffman S, Nüsing R, *et al.* PAF-induced pulmonary edema is partly mediated by PGE_2, EP3-receptors and potassium channels. *Am J Respir Crit Care Med* 2002; 166: 657–662.
4 Göggel R, Winoto-Morbach S, Vielhaber G, *et al.* PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide. *Nat Med* 2004; 10: 155–160.
5 Uhlig S, Gulbins E. Sphingolipids in the lungs. *Am J Respir Crit Care Med* 2008; 178: 1100–1114.
6 Gulbins E, Li PL. Physiological and pathophysiological aspects of ceramide. *Am J Physiol Regul Integr Comp Physiol* 2006; 290: R11–R26.
7 Liu P, Anderson RGW. Compartmentalized production of ceramide at the cell surface. *J Biol Chem* 1995; 45: 27129–27185.
8 Feron O, Balligand JL. Caveolins and the regulation of endothelial nitric oxide synthase in the heart. *Cardiovasc Res* 2006; 69: 788–797.
9 Miyawaki-Shimizu K, Predescu D, Shimizu J, *et al.* siRNA-induced caveolin-1 knockdown in mice increases lung vascular permeability *via* the junctional pathway. *Am J Physiol Lung Cell Mol Physiol* 2006; 290: L405–L413.
10 Feng Q, Song W, Lu X, *et al.* Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase. *Circulation* 2002; 106: 873–879.
11 Predescu D, Predescu S, Shimizu J, *et al.* Constitutive eNOS-derived nitric oxide is a determinant of endothelial junctional integrity. *Am J Physiol Lung Cell Mol Physiol* 2005; 289: L371–L381.
12 Perrotta C, De Palma C, Clementi E. Nitric oxide and sphingolipids: mechanisms of interaction and role in cellular pathophysiology. *Biol Chem* 2008; 389: 1391–1397.
13 Young JS, Rayhrer CS, Edmisten TD, *et al.* Sodium nitroprusside mitigates oleic acid-induced acute lung injury. *Ann Thorac Surg* 2000; 69: 224–227.
14 Guidot DM, Repine MJ, Hybertson BM, *et al.* Inhaled nitric oxide prevents neutrophil-mediated, oxygen radical-dependent leak in isolated rat lungs. *Am J Physiol* 1995; 269: L2–L5.
15 Benzing A, Brautigam P, Geiger K, *et al.* Inhaled nitric oxide reduces pulmonary transvascular albumin flux in patients with acute lung injury. *Anesthesiology* 1995; 83: 1153–1161.
16 Jeon SY, Kim EA, Ma YW, *et al.* Nitric oxide mediates platelet activating factor-induced microvascular leakage in rat airways. *Ann Otol Rhinol Laryngol* 2001; 110: 83–86.
17 Kubes P. Nitric oxide and microvascular permeability: a continuing dilemma. *Eur Respir J* 1997; 10: 4–5.
18 Kubes P. Nitric oxide affects microvascular permeability in the intact and inflamed vasculature. *Microcirculation* 1995; 2: 235–244.
19 Armstrong R. The physiological role and pharmacological potential of nitric oxide in neutrophil activation. *Int Immunopharmacol* 2001; 1: 1501–1512.
20 Uhlig S, Wollin L. An improved setup for the isolated perfused rat lung. *J Pharm Tox Meth* 1994; 31: 85–94.
21 Uhlig S, von Bethmann AN. Determination of vascular compliance, interstitial compliance and capillary filtration coefficient in isolated perfused rat lungs. *J Pharm Tox Meth* 1997; 32: 119–127.
22 Kaestle SM, Reich CA, Yin N, *et al.* Nitric oxide-dependent inhibition of alveolar fluid clearance in hydrostatic lung edema. *Am J Physiol Lung Cell Mol Physiol* 2007; 293: L859–L869.
23 Schnitzer JE, Oh P, Jacobson BS, *et al.* Caveolae from luminal plasmalemma of rat lung endothelium: microdomains enriched in caveolin, Ca(2+)-ATPase, and inositol trisphosphate receptor. *Proc Natl Acad Sci USA* 1995; 92: 1759–1763.
24 Kuebler WM, Uhlig U, Goldmann T, *et al.* Stretch activates PI3K-dependent NO production in pulmonary vascular endothelial cells *in situ*. *Am J Respir Crit Care Med* 2003; 168: 1391–1398.
25 Kogo H, Aiba T, Fujimoto T. Cell type-specific occurrence of caveolin-1α and -1β in the lung caused by expression of distinct mRNAs. *J Biol Chem* 2004; 279: 25574–25581.
26 Bauer PM, Yu J, Chen Y, *et al.* Endothelial-specific expression of caveolin-1 impairs microvascular permeability and angiogenesis. *Proc Natl Acad Sci USA* 2005; 102: 204–209.
27 Falk S, Göggel R, Heydasch U, *et al.* Quinolines attenuate PAF-induced pulmonary pressor responses and edema formation. *Am J Respir Crit Care Med* 1999; 160: 1734–1742.
28 McClintock DE, Ware LB, Eisner MD, *et al.* Higher urine nitric oxide is associated with improved outcomes in patients with acute lung injury. *Am J Respir Crit Care Med* 2007; 175: 256–262.
29 Filep JG, Foldes-Filep E. Modulation by nitric oxide of platelet-activating factor-induced albumin extravasation in the conscious rat. *Br J Pharmacol* 1993; 110: 1347–1352.
30 Laszlo F, Whittle BJ, Moncada S. Interactions of constitutive nitric oxide with PAF and thromboxane on rat intestinal vascular integrity in acute endotoxaemia. *Br J Pharmacol* 1994; 113: 1131–1136.
31 Kubes P. Nitric oxide affects microvascular permeability in the intact and inflamed vasculature. *Microcirculation* 1995; 2: 235–244.
32 Uhlig S, Brasch F, Wollin L, *et al.* Functional and fine structural changes in isolated rat lungs challenged with endotoxin *ex vivo* and *in vitro*. *Am J Pathol* 1995; 146: 1235–1247.
33 Garat C, Jayr C, Eddahibi S, *et al.* Effects of inhaled nitric oxide or inhibition of endogenous nitric oxide formation on hyperoxic lung injury. *Am J Respir Crit Care Med* 1997; 155: 1957–1964.
34 Ricciardolo FL, Sterk PJ, Gaston B, *et al.* Nitric oxide in health and disease of the respiratory system. *Physiol Rev* 2004; 84: 731–765.
35 Yin J, Hoffmann J, Kaestle SM, *et al.* Negative-feedback loop attenuates hydrostatic lung edema *via* a cGMP-dependent regulation of transient receptor potential vanilloid 4. *Circ Res* 2008; 102: 966–974.
36 Kubes P, Reinhardt PH, Payne D, *et al.* Excess nitric oxide does not cause cellular, vascular, or mucosal dysfunction in the cat small intestine. *Am J Physiol* 1995; 269: G34–G41.
37 Sanchez FA, Kim DD, Duran RG, *et al.* Internalization of eNOS *via* caveolae regulates PAF-induced inflammatory hyperpermeability to macromolecules. *Am J Physiol Heart Circ Physiol* 2008; 295: H1642–H1648.
38 Zhu L, He P. Platelet-activating factor increases endothelial [Ca2+]i and NO production in individually perfused intact microvessels. *Am J Physiol Heart Circ Physiol* 2005; 288: H2869–H2877.
39 Zhu L, Schwegler-Berry D, Castranova V, *et al.* Internalization of caveolin-1 scaffolding domain facilitated by Antennapedia home-

odomain attenuates PAF-induced increase in microvessel permeability. *Am J Physiol Heart Circ Physiol* 2004; 286: H195–H201.
40 Rizzo V, Morton C, DePaola N, *et al.* Recruitment of endothelial caveolae into mechanotransduction pathways by flow conditioning *in vitro*. *Am J Physiol Heart Circ Physiol* 2003; 285: H1720–H1729.
41 Der P, Cui J, Das DK. Role of lipid rafts in ceramide and nitric oxide signaling in the ischemic and preconditioned hearts. *J Mol Cell Cardiol* 2006; 40: 313–320.
42 Shah V, Cao S, Hendrickson H, *et al.* Regulation of hepatic eNOS by caveolin and calmodulin after bile duct ligation in rats. *Am J Physiol Gastrointest Liver Physiol* 2001; 280: G1209–G1216.
43 Shah V, Toruner M, Haddad F, *et al.* Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. *Gastroenterology* 1999; 117: 1222–1228.
44 Kumral A, Baskin H, Duman N, *et al.* Erythropoietin protects against necrotizing enterocolitis of newborn rats by the inhibiting nitric oxide formation. *Biol Neonate* 2003; 84: 325–329.
45 Serraf A, Aznag H, Baudet B, *et al.* Pulmonary vascular endothelial growth factor and nitric oxide interaction during total cardiopulmonary bypass in neonatal pigs. *J Thorac Cardiovasc Surg* 2003; 125: 1050–1057.
46 Jin S, Yi F, Zhang F, *et al.* Lysosomal targeting and trafficking of acid sphingomyelinase to lipid raft platforms in coronary endothelial cells. *Arterioscler Thromb Vasc Biol* 2008; 28: 2056–2062.
47 Norman AW, Mizwicki MT, Norman DP. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. *Nat Rev Drug Discov* 2004; 3: 27–41.
48 Ira, Johnston LJ. Sphingomyelinase generation of ceramide promotes clustering of nanoscale domains in supported bilayer membranes. *Biochim Biophys Acta* 2008; 1778: 185–197.